Opening Ceremony

Dr Ali Alshahrani

Executive Director of Pharmacovigilance and Acting Executive Director of Drug Evaluation Saudi food and drug authority

Saudi Arabia

Deusdedit Mubangizi

Director, WHO Health Product Policy and Standards


Dr Yukiko Nakatani

Assistant Director-General, Access to Medicines and Health Products


Opening Plenary
Post-pandemic construction of health product market transparency, efficiency and fairness

Judit Rius Sanjuan

Director, Department of Innovation, Access to Medicines and Health Technologies (IMT) at PAHO/WHO


Ellen F. M. ‘t Hoen

Director of Medicines Law & Policy (ML&P)


Thomas Cueni

IFPMA Director General


Adrian van den Hoven

Director General Medicines for Europe


Ashley Miller

Executive Vice President of Global Strategy and Analysis of AdvaMed


Parallel Session 1
Improving market transparency of health products where to from now?

Lovisa Gustafsson

Vice president of the Controlling Health Care Costs program at the Commonwealth Fund


Yusi Anggriani

Professor in the Clinical and Community Pharmacy at Universitas Pancasila in Jakarta Indonesia


Fatimah Al Hussain

Pharmacoeconomic Section Head at Saudi Food & Drug Authority

Saudi Arabia

Dr Quinn Grundy

Assistant Professor with the Lawrence Bloomberg Faculty of Nursing at the University of Toronto


Dr Andy Gray

Senior Lecturer in the Division of Pharmacology, Discipline of Pharmaceutical Sciences, University of KwaZulu-Natal

South Africa

Momir Radulović

Slovenian Medicines and Medical Devices Agency


Parallel Session 2
Strengthening pharmaceutical supply resilience for times of crisis: Ensuring access and affordability

Dr Daniela Marreco Cerqueira

Executive Secretary, Medicines Market Regulation Committee (SCMED), Brazilian Health Regulatory Agency [ANVISA]


Anchalee Jitruknatee


Division of National Drug Policy, Food and Drug Administration, Thailand

Ashodra Jaishika Gautam

Pharmacist, Ministry of Health and Medical Services


Lisa Hedman

Senior Advisor, WHO Division of Access To Medicines and Health Products (MHP)


Victor Mendonca

Chair of the Generic Market Access Committee at Medicines for Europe, and Head of Corporate Affairs Europe, Viatris 


Dr Prashant Yadav

Affiliate Professor of Technology and Operations at INSEAD and Academic Director of the INSEAD Africa Initiative


Dr Charles Senessie

Deputy Minister of Health, Ministry of Health Sierra Leone

Sierra Leone

Dr Elizabeth Pisani

Visiting Professor at the Faculty of Pharmacy at Universitas Pancasila


Parallel Session 3
Using real-world evidence in the real world: are regulatory and pricing decisions better aligned with health system goals?

Dr Sunu Alice Cherian

Pushpagiri College of Dental Sciences


Dr Fatima Suleman


South Africa

Dr Joseph S. Ross

Professor of Medicine (General Medicine) and of Public Health (Health Policy and Management) at the Yale School of Medicine

United States of America

Dr Graciela Fernández

Doctora en Medicina y Médico Intensivista egresada de la Facultad de Medicina de la Universidad de la República (UdelaR)


Dr Wee Hwee Lin

Associate Professor at the Saw Swee Hock School of Public Health (SSHSPH), National University of Singapore


Prof Ambroise Wonkam

Professor of Genetic Medicine, and Director of McKusick-Nathans Institute, and Department of Genetic Medicine, Johns Hopkins


Dr Patrice Verpillat

Head of the Real World Evidence (RWE) Workstream at the European Medicines Agency (EMA)


Plenary Session 2

Negotiating fair pricing – opportunities, powers, promises


Dr Yupadee Sirisinsuk

Deputy  Secretary-General, National Health Security Office


Dr Richard Torbett

Chief Executive, ABPI 


Dr Sabine Vogler

Head of the Pharmacoeconomics Department of the Austrian National Public Health Institute


Dr Suerie Moon

Co-Director of the Global Health Centre and Professor of Practice in the International Relations/Political Science Department at the Geneva Graduate Institute


Dr Anban Pillay

Deputy Director General at the National Department of Health in South Africa

South Africa

Valérie Paris

Senior policy analyst - Health Division Organisation for Economic Co-operation and Development


Anthony D. So

Professor of the Practice at the Johns Hopkins Bloomberg School of Public Health

United States of America

Billy Mweetwa

Former Director General, Zambia Medicines & Medical Supplies Agency (ZAMMSA)


Charles Gore

Executive Director of the Medicines Patent Pool (MPP)


Parallel Session 4

The untapped potential of biosimilars: how to ensure affordable access?


Julie Maréchal-Jamil

Director Biosimilars Policy & Science - Medicines for Europe


Dorthe Bartels

Strategic advisor and negotiator for new medicine, Amgros


Salomé Meyer

GAVI Civil Society Constituency Steering Committee

South Africa

Claudia Martínez

Head of Research for the Access to Medicine Foundation


Sultan Al Harbi

Head of Pharmaceutical Pricing Section-Saudi Food And Drug Authority

Saudi Arabia

Dr Steven Morgan

Economist and Professor of health care policy at the University of British Columbia


Parallel Session 5

Advancing accessibility and affordability of medical devices and in vitro diagnostics by bridging the information gap and complexity


Vishakha Sharma

Market Research Officer, UNICEF


Friederike Windisch

Senior Health Expert at the Austrian National Public Health Institute


Millicent Alooh

Honorable National Secretary, Association of Medical Engineering


Adriana Velazquez Berumen

Senior adviser and team lead of medical devices and in vitro diagnostics at the World Health Organization


Andrew Rintoul

Assistant Secretary at the Australian Government Department of Health and Aged Care


Dr David Henri Beran

Assistant Professor at the Faculty of Medicine at the University of Geneva


Dr Susan Horton

Professor Emeritus of global health economics from the University of Waterloo


Mohamad Wehbi

Technical Officer at WHO EMRO


Dr Trevor Gunn

Vice President - International Relations for Medtronic


Dr Stijn Deborggraeve

Diagnostics Advisor Infectious Diseases at Médecins Sans Frontières (MSF) Access Campaign


Parallel Session 6

How to pay for universal access to medicines for rare diseases and by whom? The great conundrum


Dr Haruka Nakada

Staff Scientist, Kanagawa University of Human Services


Dr Hana Al-Abdulkarim

Director of Drug Policy and Economic Center DPEC in NGHA (Riyadh, KSA)

Saudi Arabia

Simone Boselli

Member of the European and International Advocacy team


Anne-Sophie Chalandon

Head of Global Rare Diseases and CGT Policy at Sanofi


Dr Bhagwan Singh Charan

Assistant Director General (ADG) at Directorate General of Health Services, Ministry of Health & Family Welfare Government of India


Kevin Pothier

Director of Policy and Economic Analysis Patented Medicine Prices Review Board


Dr Izzuna Mudla Mohamed Ghazali

Deputy Director of the Medical Development Division, Ministry of Health Malaysia


Sharmila Nebhrajani

Chairman of the National Institute for Health and Care Excellence (NICE)

United Kingdom

Dr Ayman El-Hattab

Professor, College of Medicine, University of Sharjah

United Arab Emirates

Dr Roberto Giugliani

Professor at the Department of Genetics of the Federal University of Rio Grande do Sul (UFRGS)


Parallel Session 7

Using HTA to improve affordable access to essential medicines


Andrew Mirelman

Technical Officer, World Health Organization Headquarters


Saudamini Vishwanath Dabak

Head of HITAP’s International Unit (HIU)


Dr Jessica Ochalek

Centre for Health Economics (CHE) at the University of York

United Kingdom

Dr Mouna Jameleddine

Head of the HTA Department at the Tunisian National Authority for Assessment and Accreditation in Health (INEAS)


Prof Dr Andres Pichon-Riviere

Director of the Health Economics and Technology Assessment Department at the IECS


Dr Rabia Sucu

President of Health Technology Assessment International Society and Senior Principal Technical Advisor for Health Policy and Financing in the Management Sciences for Health (MSH)

United States of America

Dr Panos Kanavos

Associate Professor of International Health Policy in the Department of Health Policy at London School of Economics and Political Science, Deputy Director at LSE Health and Programme Director of the Medical Technology Research Group (MTRG

United Kingdom

Dr YingYao Chen

Professor of Health Technology Assessment at Fudan University School of Public Health


Dr Jacqui Miot

Division Director of the Health Economics and Epidemiology Research Office (HE2RO)

South Africa

Parallel Session 8

Intellectual property challenges to promote innovation and timely global equitable access and affordability


Mustaqeem de Gama

Director of legal international trade, Afrigen/Department of Trade, Industry and Competition

South Africa

Boyan Konstantinov

Policy Specialist, HIV, Health and Development, United Nations Development Programme


Heba Wanis

Researcher in Public Health and Pharmaceutical Policies, Third World Network


Paul Fure Torkehagen

Vice President of International Business Development at Medigen Vaccine Biologics Corp


Sergiy Kondratyuk

Project Manager, International Treatment Preparedness Coalition (IPTC) Global


Dr Viviana Muñoz Tellez

Programme Coordinator of the Health, Intellectual Property and Biodiversity (HIPB) Programme of the South Centre


H.E. Ambassador Shara Duncan-Villalobos 

Ambassador Deputy Permanent Representative of Costa Rica to the United Nations Office

Costa Rica

Parallel Session 9

In a post pandemic world, how can policies mitigate drug shortages and increase access to patients while maintaining affordability?


Dr Alejandro Ernesto Svarch Pérez

Head of Commission, Federal Commission for the Protection against Health Risks


Christopher Lim

Chief, PAHO Strategic Fund, Pan-American Health Organization


Abdulrazaq Al-Jazairi

Director, Clinical Trials Transformation Initiative (CTTI) Division. Clinical Pharmacy Consultant, Cardiology

Saudi Arabia

Suzannah Chapman

Health Policy Analyst, Organisation for Economic Co-operation and Development


Dr Nehal Gamal El-Din Ebrahim Abou Youssef

Head of administration of Drug availability and business continuity


Prof Abderazzek Hedhili

General Director, National regulatory agency of medicines and health products


Mansour Al Howaimel

Senior Manager of pharmacoeconomics department in National Unified Procurement Company

Saudi Arabia

Jim Keon

Canadian Generic Pharmaceutical Association(CGPA)/International Generic and Biosimilar Medicines Association (IGBA)


Abdullah H. AL-Hatareshah

Clinical pharmacist and Executive Director for Regulatory Affairs at the Saudi Food and Drug Authority

Saudi Arabia

Plenary Session 3

Optimizing pricing policies and strategies by buyers and sellers—getting it right


Dr Katrina Perehudoff

Health scientist and legal scholar, University of Amsterdam, Kingdom of the Netherlands


Adriana María Robayo García

Executive Director, Instituto de Evaluación Tecnologica en Salud


Deusdedit Mubangizi

Director, WHO Health Product Policy and Standards


Dr Yukiko Nakatani

Assistant Director-General, Access to Medicines and Health Products


Tamara Schudel

Vice President and Head of Global Policy at Roche


Abraham S.T. Weekes

Senior Technical Specialist at Organization of Eastern Caribbean States Pharmaceutical


Dr Manju Sengar

Professor and Head Department of Medical Oncology, Tata Memorial Centre


Dr Veronika Wirtz

Professor of Global Health at the Boston University School of Public Health

United States of America

Dr Zaheer Babar

Editor-in-Chief, Journal of Pharmaceutical Policy and Practice

United Kingdom

Francis Arickx

Head of the directorate Reimbursement of Medicines and Pharmaceutical Policy within the Health Care Department at the National Institute for Health and Disability Insurance (NIHDI RIZIV/INAMI)